MannKind Corp - Company Profile
Powered by 
All the data and insights you need on MannKind Corp in one report.
$295
- Save hours of research time and resources with
our up-to-date MannKind Corp Strategy Report
- Understand MannKind Corp position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
MannKind Corp (MannKind) is a biopharmaceutical company that develops and commercializes inhaled therapeutic products for patients suffering from diabetes and pulmonary arterial hypertension. Its flagship product, Afrezza is a rapid-action inhaled insulin used to control high blood sugar in adults with type 1 and type-2 diabetes. It consists of a dry powder formulation of human insulin delivered from small and portable inhaler. The company develops products based on its proprietary Technosphere formulation technology. Mannkind has manufacturing facility in Danbury, Connecticut and sells product to wholesale distributors and specialty pharmacies in the US. MannKind is headquartered in Westlake Village, California, the US.
Headquarters
United States of America
Address
1 Casper Street, Danbury, Connecticut, 06810
Website
mannkindcorp.com
Telephone
1 818 6615000
No of Employees
414
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
MNKD (NASD)
Revenue (2022)
$199.0M
99.4%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
86.3%
(2022 vs 2021)
Market Cap*
$1.1B
Net Profit Margin (2022)
XYZ
93.2%
(2022 vs 2021)
* As of and is in US$
MannKind Corp premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Afrezza – for Diabetes | Afrezza |
| V-Go- wearable insulin delivery device | Technosphere |
| Technology: | Bluhale |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Plans/Strategy | In December, the company along with Millstone Medical, ReST Therapeutics, and Revalia Bio announced their plans to expand their operations in Connecticut, the US. |
| 2023 | Others | In October, the company expands its patent portfolio with new clofazimine formulation patent. |
| 2022 | Asset Purchase | In May, the company acquired V-Go insulin delivery device from Zealand Pharma A/S. |
Competitor Comparison
| Key Parameters | MannKind Corp | Pfizer Inc | Sanofi | Eli Lilly and Co | Novo Nordisk AS |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | France | United States of America | Denmark |
| City | Danbury | New York | Paris | Indianapolis | Bagsvaerd |
| State/Province | Connecticut | New York | Ile-de-France | Indiana | - |
| No. of Employees | 414 | 88,000 | 87,994 | 43,000 | 63,370 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| James S. Shannon, M.D | Chairman | Executive Board | 2020 | 66 |
| Michael E. Castagna | Director; Chief Executive Officer | Executive Board | 2017 | 46 |
| Steven Binder | Chief Financial Officer | Senior Management | 2017 | 60 |
| Lauren Sabella | Chief Operating Officer; Executive Vice President | Senior Management | 2023 | 62 |
| Burkhard Blank, MD | Chief Medical Officer; Executive Vice President - Research and Development | Senior Management | 2023 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward